Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 123
Filtrar
1.
São Paulo med. j ; 138(1): 64-68, Jan.-Feb. 2020. tab
Artigo em Inglês | LILACS | ID: biblio-1099380

RESUMO

ABSTRACT BACKGROUND: Endometrial polyps are common in postmenopausal women, and the effect of tamoxifen use (a risk factor for endometrial polyps) on their pathogenesis is unclear. OBJECTIVES: To evaluate the expression of hormone receptors and markers for proliferation/apoptosis (Ki-67 and Bcl-2) in endometrial polyps in postmenopausal users and nonusers of tamoxifen. DESIGN AND SETTING: Cross-sectional analytical study in a tertiary-level academic hospital. METHODS: 46 women (14 tamoxifen users and 32 nonusers) with postmenopausal bleeding underwent hysteroscopic resection of endometrial polyps. Polyp samples were immunohistochemically assessed for detection of Ki-67, Bcl-2 and estrogen and progesterone receptors. RESULTS: Analysis on the glandular component of the polyps revealed progesterone receptor expression in the polyps of 96.9% of the nonusers of tamoxifen, and 92.3% of the tamoxifen users (P = 0.499). All polyps in nonusers and 92.3% of those in users were also positive for estrogen receptors (P = 0.295). Ki-67 was expressed in 75% of the polyps in the tamoxifen users and 82.8% of those in the nonusers. All endometrial polyps expressed Bcl-2. CONCLUSIONS: The immunohistochemical analysis on endometrial polyps demonstrated that, although tamoxifen is considered to be a risk factor for endometrial polyps, there were no significant differences in the expression of hormone receptors between users and nonusers of tamoxifen. There were no between-group differences in Ki-67 and Bcl-2 expression, and all patients displayed inhibition of apoptosis by Bcl-2, thus supporting the theory that polyps develop due to inhibition of apoptosis, and not through cell proliferation.


Assuntos
Humanos , Feminino , Tamoxifeno/efeitos adversos , Pós-Menopausa , Endométrio , Pólipos , Estudos de Casos e Controles , Estudos Transversais , Antagonistas de Estrogênios/efeitos adversos
2.
Journal of Breast Cancer ; : 86-95, 2019.
Artigo em Inglês | WPRIM | ID: wpr-738413

RESUMO

PURPOSE: Discontinuation of hormone therapy is known to lead to a poorer prognosis in breast cancer patients. We aimed to investigate the prescription gap as a prompt index of medication adherence by using prescription data extracted from patient electronic medical records. METHODS: A total of 5,928 patients diagnosed with invasive, non-metastatic breast cancer, who underwent surgery from January 1, 1997 to December 31, 2009, were enrolled retrospectively. The prescription data for 4.5 years of hormonal treatment and breast cancer-related events after treatment completion were analyzed. We examined the characteristics and prognoses of breast cancer in patients with and without a 4-week gap. RESULTS: Patients with a gap showed a significantly higher risk of breast cancer recurrence, distant metastasis, breast cancer-specific death, and overall death after adjustment (hazard ratio [HR], 1.389; 95% confidence interval [CI], 1.089–1.772; HR, 1.568; 95% CI, 1.158–2.123; HR, 2.108; 95% CI, 1.298–3.423; and HR, 2.102; 95% CI, 1.456–3.034, respectively). When patients were categorized based on gap summation, the lower third (160 days) and fourth (391 days) quartiles showed a significantly higher risk of distant metastasis (HR, 1.758; 95% CI, 1.186–2.606 and HR, 1.844; 95% CI, 1.262–2.693, respectively). CONCLUSION: A gap of > 4 weeks in hormonal treatment has negative effects on breast cancer prognosis, and can hence be used as a sentinel index of higher risk due to treatment non-adherence. Further evaluation is needed to determine whether the gap can be used as a universal index for monitoring the adherence to hormonal treatment.


Assuntos
Humanos , Neoplasias da Mama , Mama , Registros Eletrônicos de Saúde , Antagonistas de Estrogênios , Adesão à Medicação , Metástase Neoplásica , Prescrições , Prognóstico , Recidiva , Estudos Retrospectivos
3.
Braz. j. med. biol. res ; 51(12): e7813, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-974251

RESUMO

Hereditary angioedema (HAE) is a rare autosomal dominant disease due to C1 esterase inhibitor deficiency (C1-INH). The disease is characterized by subcutaneous and submucosal edema in the absence of urticaria due to the accumulation of bradykinin. This descriptive study aimed to evaluate the clinical characteristics of patients with a confirmed diagnosis of HAE referred to our Outpatient Clinic between December 2009 and November 2017. Fifty-one patients (38 F, 13 M) with a mean age of 32 years (range: 7-70 y) were included. Family history of HAE was reported in 70% (36/51) of the cases; 33/46 patients became symptomatic by 18 years of age. The median time between onset of symptoms and diagnosis was 13 years (3 mo-50 y). The most frequent triggering factors for attacks were stress (74.4%), trauma (56.4%), and hormonal variations (56%). The main symptoms were subcutaneous edema in 93.5% (43/46) of patients, gastrointestinal symptoms in 84.8% (39/46), and obstruction in the upper airways in 34.8% (16/46). Hospitalization occurred in 65.2%, of whom 13.3% had to be transferred to the Intensive Care Unit. Prophylactic treatment was instituted in 87% (40/46) of patients, and 56.5% (26/46) required additional treatment to control attacks. Owing to our data collection over a period of 8 years, a significant number of patients were identified by this HAE reference center. Despite early recognition and prophylactic treatment, a high percentage of patients were hospitalized. HAE is still diagnosed late, reinforcing the need for more reference centers specialized in diagnosis and educational projects for health professionals.


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Proteína Inibidora do Complemento C1/análise , Angioedema Hereditário Tipos I e II/etiologia , Angioedema Hereditário Tipos I e II/sangue , Estresse Psicológico/complicações , Fatores Desencadeantes , Fatores de Risco , Resultado do Tratamento , Idade de Início , Antagonistas de Estrogênios/uso terapêutico , Angioedema Hereditário Tipos I e II/prevenção & controle , Angioedema Hereditário Tipos I e II/tratamento farmacológico , Profilaxia Pós-Exposição/métodos , Trauma Psicológico/complicações , Hospitalização , Antifibrinolíticos/uso terapêutico , Nefelometria e Turbidimetria/métodos
4.
Braz. j. med. biol. res ; 51(1): e6799, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-889013

RESUMO

Arthritis is positively associated with the decline of sex hormones, especially estrogen. Tamoxifen (TMX) is a selective estrogen receptor modulator, possessing agonist or antagonistic activity in different tissues. Thus, the objective of this study was to investigate the effect of TMX on the zymosan-induced arthritis model. Female Swiss normal and ovariectomized (OVX) mice were divided into groups and treated for five days with TMX (0.3, 0.9 or 2.7 mg/kg) or 17-β-estradiol (E2, 50 µg/kg). On the fifth day, arthritis was induced and 4 h later, leukocyte migration into joint cavities was evaluated. The neutrophil migration in OVX animals, but not in normal mice, treated with TMX (all tested doses) was significantly decreased compared with mice that received the vehicle (P≤0.05). Similarly, this effect was also demonstrated in the E2-treated group. Therefore, the present study demonstrates that TMX presented agonist effects in inhibiting neutrophil migration and preventing arthritis progression in OVX mice.


Assuntos
Animais , Feminino , Coelhos , Artrite Experimental/tratamento farmacológico , Tamoxifeno/farmacologia , Ovariectomia , Moduladores Seletivos de Receptor Estrogênico/farmacologia , Tamanho do Órgão/efeitos dos fármacos , Fatores de Tempo , Útero/efeitos dos fármacos , Zimosan , Movimento Celular/efeitos dos fármacos , Resultado do Tratamento , Ciclo Estral/efeitos dos fármacos , Modelos Animais de Doenças , Antagonistas de Estrogênios/farmacologia , Ensaios de Migração de Leucócitos , Neutrófilos/efeitos dos fármacos
5.
An. bras. dermatol ; 92(5): 655-660, Sept.-Oct. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-887019

RESUMO

Abstract: Background: Hereditary angioedema is a rare autosomal dominantly inherited immunodeficiency disorder characterized by potentially life-threatening angioedema attacks. Objective: We aimed to investigate the clinical and genetic features of a family with angioedema attacks. Methods: The medical history, clinical features and C1-INH gene mutation of a Turkish family were investigated and outcomes of long-term treatments were described. Results: Five members had experienced recurrent swellings on the face and extremities triggered by trauma. They were all misdiagnosed as familial Mediterranean fever (FMF) depending on frequent abdominal pain and were on colchicine therapy for a long time. They had low C4 and C1-INH protein concentrations and functions. A mutation (c.1247T>A) in C1-INH gene was detected. They were diagnosed as having hereditary angioedema with C1-INH deficiency (C1-INH hereditary angioedema) for the first time. Three of them benefited from danazol treatment without any significant adverse events and one received weekly C1 esterase replacement treatment instead of danazol since she had a medical history of thromboembolic stroke. Study limitations: Small sample size of participants. Conclusion: Patients with C1-INH hereditary angioedema may be misdiagnosed as having familial Mediterranean fever in regions where the disorder is endemic. Medical history, suspicion of hereditary angioedema and laboratory evaluations of patients and their family members lead the correct diagnoses of hereditary angioedema. Danazol and C1 replacement treatments provide significant reduction in hereditary angioedema attacks.


Assuntos
Humanos , Masculino , Feminino , Criança , Adulto , Pessoa de Meia-Idade , Danazol/uso terapêutico , Antagonistas de Estrogênios/uso terapêutico , Proteína Inibidora do Complemento C1/genética , Angioedemas Hereditários/tratamento farmacológico , Linhagem , Fatores de Tempo , Turquia , Sequência de Bases , Amplificação de Genes , Resultado do Tratamento , Proteína Inibidora do Complemento C1/uso terapêutico , Angioedemas Hereditários/diagnóstico , Angioedemas Hereditários/genética , Mutação
6.
Arq. neuropsiquiatr ; 75(9): 620-624, Sept. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-888327

RESUMO

ABSTRACT Objective To describe the evolution of 15 patients who were treated for difficult-to-control episodic and chronic cluster headaches with clomiphene. Methods Clomiphene treatment was used for seven chronic and eight episodic cluster headache patients. The chronic patients were refractory to the medication being used, and the episodic patients, in addition to being resistant to conventional medication, had longer cluster headache periods, exceeding the average time of previous cluster cycles. Our main analysis was of the time to pain-free, complete remission, and the length of pain-free time and complete remission. Results Clomiphene was used for 45-180 days. The average time to being pain-free was 15 days and cluster remission was up to 60 days. The average time between being pain-free until cluster remission was 26 days. Conclusions Clomiphene treatment was significantly efficient. It interrupted chronicity in all patients, suggesting the capability of changing the pattern of attacks. It proved to be safe and well tolerated.


RESUMO Objetivo Descrever a evolução de 15 casos de cefaleia em salvas de difícil controle, episódicos e crônicos, tratados com clomifeno. Métodos Foram tratados 7 casos crônicos e 8 episódicos. Os crônicos, refratários aos medicamentos preventivos em uso e os episódicos, além de refratários, apresentaram salva mais longa que as anteriores. Foram analisados o tempo para a ausência das crises, fim da salva e o tempo entre os dois parâmetros. Resultados O clomifeno foi usado por 45 a 180 dias. A média de tempo para a remissão das crises foi de 15 dias e da salva foi de 60 dias. A média entre o fim das crises e da salva foi de 26 dias. Conclusão O clomifeno foi eficaz em ambos os padrões. Foi capaz de interromper a cronicidade em todos os casos, o que sugere uma ação neuromodulatória capaz de mudar o padrão das crises. Mostrou-se seguro e bem tolerado.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Clomifeno/uso terapêutico , Cefaleia Histamínica/tratamento farmacológico , Transtornos da Cefaleia/tratamento farmacológico , Antagonistas de Estrogênios/uso terapêutico , Doença Crônica , Resultado do Tratamento
7.
Int. braz. j. urol ; 42(6): 1190-1194, Nov.-Dec. 2016. graf
Artigo em Inglês | LILACS | ID: biblio-828942

RESUMO

ABSTRACT Objective: Previous series have demonstrated that Clomiphene Citrate (CC) is an effective treatment to increase Total Testosterone (TT) in Late Onset Hypogonadism (LOH) patients. However, what happens to TT levels after ending CC treatment is still debatable. The objective of this study is to evaluate TT levels 3 months after the discontinuation of CC in patients with LOH who were previously successfully treated with the same drug. Materials and Methods: Twenty-seven patients with LOH that were successfully treated (achieved TT levels >11nmol/l) with CC 50mgs daily for 50 days were prospectively recruited in our Andrological outpatient clinic. CC was then stopped for 3 months and TT levels were measured at the end of this period. Results: Mean TT level before discontinuation of CC was 22.7±8.1nmol/L (mean±SD). Three months after discontinuation, mean TT level significantly decreased in all patients, 10.2±3.9nmol/l (p<0.01). Twenty-one patients (78%) decreased TT levels under 11nmol/L. Six patients (22%) had TT levels that remained within the normal recommended range (≥11nmol/l). No statistical significant differences were observed between both groups. Conclusion: In the short term LOH does not seem to be a reversible condition in most patients after CC treatment. More studies with longer follow-up are needed to evaluate the kinetics of TT in LOH.


Assuntos
Humanos , Adulto , Idoso , Testosterona/sangue , Clomifeno/uso terapêutico , Antagonistas de Estrogênios/uso terapêutico , Hipogonadismo/terapia , Hormônio Luteinizante/sangue , Estudos Prospectivos , Seguimentos , Resultado do Tratamento , Clomifeno/administração & dosagem , Antagonistas de Estrogênios/administração & dosagem , Hormônio Foliculoestimulante/sangue , Hipogonadismo/cirurgia , Pessoa de Meia-Idade
8.
Rev. bras. ginecol. obstet ; 38(12): 615-622, Dec. 2016. tab
Artigo em Inglês | LILACS | ID: biblio-843883

RESUMO

ABSTRACT Breast cancer is the most common type of cancer and the leading cause of cancer-related death among women worldwide. Hormone receptor-positive (HRþ) tumors represent the most common form of this disease, with more than 70% of breast cancers expressing these receptors. Response and benefit to neoadjuvant chemo-therapy (NCT) varies according to HR expression, with lower responses in luminal tumors as compared with hormone receptor-negative (HR-) and human epidermal growth factor receptor 2-positive (HER2þ) tumors. Neoadjuvant endocrine therapy (NET) is an option for selected patients with HRþ locally advanced breast cancer. Neoadjuvant endocrine therapy has a favorable toxicity profile, and is associated with benefits such as having low cost and being more easily available even for cancer care professionals outside major urban areas or tertiary centers. These factors are particularly relevant, as 70% of breast cancer deaths occur in women from low-income and middle-income countries. Additionally, NET is being increasingly explored, not simply to allow for less extensive surgery, but also as a scientific tool, with the use of biomarkers to predict outcomes in adjuvant trials and for the individual patient. This review details the current and most relevant evidence about NET for breast cancer as well as the future directions of this field.


RESUMO O câncer de mama é o mais comum, e a principal causa de mortalidade por câncer em mulheres de todo o mundo. Os tumores com receptor hormonal (RH) positivo representam o tipo mais comum desta doença. O benefício e as taxas de resposta à quimioterapia neoadjuvante variam de acordo com a expressão de RH, sendo mais baixa nos tumores luminais em comparação com tumores HER2 positivos ou triplo-negativos. A hormonioterapia neoadjuvante, uma opção para pacientes selecionados com tumores RH positivo localmente avançados, apresenta melhor perfil de tolerabilidade e segurança, e está associada com benefícios adicionais, como baixo custo e fácil acesso. Estes fatores são relevantes, uma vez que 70% das mortes por câncer de mama acontecem em mulheres de países pobres ou em desenvolvimento. Além disso, a hormonioterapia neoadjuvante vem sendo explorada como uma ferramenta científica, ao possibilitar o estudo de biomarcadores que podem predizer desfechos tanto para pacientes individuais quanto para ensaios clínicos em adjuvância. Este artigo de revisão detalha o conhecimento atual e as evidências mais relevantes sobre hormonioterapia neoadjuvante em câncer de mama, assim como perspectivas futuras nesta área.


Assuntos
Humanos , Feminino , Antineoplásicos Hormonais/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Antagonistas de Estrogênios/uso terapêutico , Terapia Neoadjuvante/métodos , Inibidores da Aromatase/uso terapêutico , Receptor ErbB-2/metabolismo , Receptores de Estrogênio/metabolismo
9.
Rev. méd. Chile ; 144(11): 1377-1381, nov. 2016. ilus
Artigo em Espanhol | LILACS | ID: biblio-845458

RESUMO

Background: The decline of estrogen levels increases cardiovascular risk in women. Platelets express estrogen receptors and 17β-estradiol- (E2) can produce a protective effect on thrombus formation. The hydroxylation of cholesterol generates several sterols and 27-hydroxycholesterol (27HC) predominates in circulation. Aim: To evaluate the effect of 27HC as an endogenous antagonist of the anti-aggregating properties of E2 in platelets of postmenopausal women. Material and Methods: Platelet function of postmenopausal women was evaluated ex-vivo. Platelets pre-incubated with 27HC in the presence or absence of E2, were stimulated with collagen. Aggregation was evaluated using turbidimetry using a Chrono-log aggregometer. Results: Collagen-stimulated platelet aggregation was significantly inhibited by E2. The inhibitory effect of E2 on collagen-stimulated platelet aggregation was significantly reversed in the presence of 27HC. Conclusions: The suppressive effect of E2 on platelet aggregation is inhibited by 27HC, which could contribute to increase cardiovascular risk in postmenopausal women.


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Idoso , Agregação Plaquetária/efeitos dos fármacos , Pós-Menopausa/sangue , Antagonistas de Estrogênios/farmacologia , Estrogênios/farmacologia , Hidroxicolesteróis/farmacologia , Valores de Referência , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Inibidores da Agregação Plaquetária , Doenças Cardiovasculares/etiologia , Fatores de Risco , Colágeno/farmacologia , Estatísticas não Paramétricas , Estradiol/metabolismo
10.
Journal of Korean Medical Science ; : 310-314, 2016.
Artigo em Inglês | WPRIM | ID: wpr-225575

RESUMO

CYP2D6 is primarily responsible for the metabolism of clomiphene citrate (CC). The purpose of the present study was to investigate the relationship between CYP2D6 genotypes, concentrations of CC and its major metabolites and drug response in infertility patients. We studied 42 patients with ovulatory dysfunction treated with only CC. Patients received a dose of 100 mg/day CC on days 3-7 of the menstrual cycle. CYP2D6 genotyping and measurement of CC and the major metabolite concentrations were performed. Patients were categorized into CC responders or non-responders according to one cycle response for the ovulation. Thirty-two patients were CC responders and 10 patients were non-responders with 1 cycle treatment. The CC concentrations were highly variable within the same group, but non-responders revealed significantly lower (E)-clomiphene concentration and a trend of decreased concentrations of active metabolites compared to the responders. Nine patients with intermediate metabolizer phenotype were all responders. We confirmed that the CC and the metabolite concentrations were different according to the ovulation status. However, our results do not provide evidence for the contribution of CYP2D6 polymorphism to either drug response or CC concentrations.


Assuntos
Adulto , Feminino , Humanos , Cromatografia Líquida de Alta Pressão , Clomifeno/sangue , Citocromo P-450 CYP2D6/genética , Antagonistas de Estrogênios/análise , Genótipo , Infertilidade/tratamento farmacológico , Indução da Ovulação , Fenótipo , Polimorfismo Genético , República da Coreia , Espectrometria de Massas em Tandem
11.
Acta Pharmaceutica Sinica ; (12): 154-161, 2015.
Artigo em Chinês | WPRIM | ID: wpr-251802

RESUMO

To investigate the effect of naringenin on ovariectomy-induced postmenopausal osteoporosis comprehensively and systemically, thirty-two virgin Sprague-Dawley rats about 3-month-old were used and randomly divided into 4 groups: sham control group (Sham), OVX control group (OVX), naringenin treatment group and 17β-estradiol (E2) treatment group. After 12 weeks treatment with different drugs, 24 h urine were collected, organs were weighed and the organ indies were computed. Uterine pathological changes were observed by making paraffin section. Biochemical parameters and bone turnover markers: serum osteocalcin (BGP) and urine deoxypyridinoline (DPD) were analyzed with automatic biochemical analyzer or ELISA assay. Bone mineral density (BMD) and bone mineral content (BMC) were analyzed by DEXA, bone biomechanical properties was measured by three point bending test and the trabecular bone microarchitecture was evaluated by Micro CT. From the results, we can see that: the gaining of weight and the increasing of bone turnover markers such as serum BGP and urinary DPD could be inhibited by naringenin. The treatment could also enhance the bone strength and prevent the deterioration of trabecular microarchitecture, increase the bone volume, trabecular number and thickness, and decrease the trabecular space. The effects mentioned above were not accompanied with stimulating effects on uterus. Long-term using of naringenin had no obvious influence on other organs and the liver and kidney functions. The study suggests that naringenin had obvious antiosteoporotic effect on ovariectomized rats and it had the potential value for the treatment of postmenopausal osteoporosis.


Assuntos
Animais , Feminino , Ratos , Aminoácidos , Urina , Densidade Óssea , Modelos Animais de Doenças , Estradiol , Farmacologia , Antagonistas de Estrogênios , Farmacologia , Flavanonas , Farmacologia , Osteocalcina , Sangue , Osteoporose , Tratamento Farmacológico , Ovariectomia , Ratos Sprague-Dawley , Útero , Patologia
12.
Hist. ciênc. saúde-Manguinhos ; 21(4): 1179-1196, Oct-Dec/2014.
Artigo em Português | LILACS | ID: lil-732513

RESUMO

O artigo analisa o livro Boys in white: student culture in medical school, de Howard S. Becker, Blanche Geer, Everett C. Hughes e Anselm Strauss, considerado um dos modelos de pesquisa qualitativa em sociologia. A análise aborda as trajetórias dos autores, do livro, da pesquisa qualitativa e dos estudantes de medicina, enfatizando sua importância nas origens da sociologia médica e da sociologia da educação médica. Na trajetória dos autores são apresentados aspectos biobibliográficos; na da pesquisa qualitativa, o modo como essa metodologia de investigação atravessa a construção do trabalho de campo; e na dos estudantes, sua forma de atravessar os primeiros anos da escola médica e construir sua própria “cultura do estudante”.


This article analyzes Boys in white: student culture in medical schoolby Howard S. Becker, Blanche Geer, Everett C. Hughes and Anselm Strauss, considered a model of qualitative research in sociology. The analysis investigates the trajectories of the authors, the book, qualitative analysis, and the medical students, emphasizing their importance in the origins of medical sociology and the sociology of medical education. In the trajectory of the authors, bibliographical information is given. The trajectory of qualitative research focuses on how this methodology influences the construction of the field. The investigation of the students’ trajectory shows how they progress through their first years at medical school to build their own student culture.


Assuntos
Animais , Feminino , Camundongos , Adenocarcinoma/tratamento farmacológico , Antimetabólitos Antineoplásicos/farmacologia , Antineoplásicos Hormonais/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Apoptose/efeitos dos fármacos , Neoplasias da Mama/tratamento farmacológico , Estrogênios , Antagonistas de Estrogênios/farmacologia , Inibidores do Crescimento/farmacologia , Neoplasias Hormônio-Dependentes/tratamento farmacológico , Fenilacetatos/farmacologia , /biossíntese , Tamoxifeno/farmacologia , Adenocarcinoma/patologia , Antimetabólitos Antineoplásicos/administração & dosagem , Antineoplásicos Hormonais/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Neoplasias da Mama/patologia , Diferenciação Celular/efeitos dos fármacos , Divisão Celular/efeitos dos fármacos , Sinergismo Farmacológico , Genes ras , Camundongos Nus , Transplante de Neoplasias , Neoplasias Hormônio-Dependentes/patologia , /fisiologia , Fenilacetatos/administração & dosagem , /genética , Transfecção , Tamoxifeno/administração & dosagem , Células Tumorais Cultivadas/efeitos dos fármacos
13.
Korean Journal of Urology ; : 756-763, 2014.
Artigo em Inglês | WPRIM | ID: wpr-227268

RESUMO

PURPOSE: Limited studies have shown antifibrotic effects of pentoxifylline, captopril, simvastatin, and tamoxifen. No comparisons are available of the effects of these drugs on prevention of renal and bladder changes in partial urethral obstruction (PUO). MATERIALS AND METHODS: The rats were divided into six groups (n=7). The sham-operated rats (group I) only underwent laparotomy and did not receive any treatments. The PUO groups (group II-VI) received normal saline (PUO+NS), pentoxifylline (100 mg/kg/d; PUO+PEN), captopril (35 mg/kg/d; PUO+CAP), simvastatin (15 mg/kg/d; PUO+SIM), or tamoxifen (10 mg/kg/d; PUO+TAM) by gavage for 28 days. Then, the volume and/or length of the kidney components (tubules, vessels, and fibrous tissue) and the bladder components (epithelial and muscular layers, fibrous tissue, fibroblast and fibrocyte number) were quantitatively evaluated on the microscopic sections by use of stereological techniques. RESULTS: The volume of renal and bladder fibrosis was significantly ameliorated in the PUO+PEN group, followed by the PUO+CAP, PUO+SIM, and PUO+TAM groups. Also, the volume and length of the renal tubules and vessels and bladder layers were more significantly protected in the PUO+PEN group, followed by the PUO+CAP, PUO+SIM, and PUO+TAM groups. CONCLUSIONS: Treatment of PUO with PEN was more effective in the prevention of renal and bladder fibrosis and in the preservation of renal and bladder structures.


Assuntos
Animais , Masculino , Ratos , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Captopril/farmacologia , Modelos Animais de Doenças , Antagonistas de Estrogênios/farmacologia , Sequestradores de Radicais Livres/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Rim/efeitos dos fármacos , Pentoxifilina/farmacologia , Sinvastatina/farmacologia , Tamoxifeno/farmacologia , Obstrução Uretral/tratamento farmacológico , Obstrução do Colo da Bexiga Urinária/tratamento farmacológico
14.
Acta odontol. venez ; 52(3)2014. tab, graf
Artigo em Espanhol | LILACS | ID: lil-778021

RESUMO

El objetivo de este estudio fue evaluar el efecto de la deficiencia de estrógenos asociada con dieta hiperlipídica sobre la integridad de la mandíbula de ratas. Para este experimento se selecionaron Ratas Wistar fueron divididas en 4 grupos: Control (C4%), Control hiperlipídica19% (C19%), ovariectomizadas 4% (OVX4%) y Ovariectomizada 19% (OVX19%). El experimento empezó con la castración (90 días), seguida de dieta hiperlipídica durante 30 días. Al fin, la sangre fue recogida para el análisis de los niveles séricos de calcio, fósforo, fosfatasa alcalina y estradiol. El fósforo disminuyó cuando hay aumento de la fosfatasa alcalina en todos los grupos en comparación con el C4%. En las vértebras L4, los pesos inmersos y húmedos aumentarán con la castración y la dieta hiperlipídica, mientras que el porcentaje de materia orgánica y minerales disminuyeron. En las mandíbulas, los pesos inmersos, húmedos y la densidad ósea aumentaran con la castración, pero disminuyeron con la combinación de castración / dieta. En las cenizas de las mandíbulas, el porcentaje de magnesio aumentó significativamente en todos los grupos. En las pruebas biomecánicas de las vértebras L4 y fémur no se encontraron diferencias significativas entre los grupos. Sin embargo, los grupos alimentados con dieta hiperlipídica tuvieron una menor resistencia a la tensión aplicada en la mandíbula. Dentro de las limitaciones del estudio, se puede notar que en estas ratas, la deficiencia de esteroides sexuales asociada con la dieta hiperlipídica influye negativamente sobre la integridad del hueso mandibular...


The aim of this study was to evaluate the effect of estrogen deficiency associated with a high fat diet on bone integrity of the jaw of rats. The pregnant rats were evaluated by vaginal cytology were 90 days old, divided into four groups: Control (C4%), Control hiperlipídica19% (C19%), ovariectomized 4% (OVX4%) and Ovariectomized19% (OVX19%). The experiment began with castration (90 days), followed by feeding with a high fat diet for 30 days. At the end, blood was collected. Jaws, vertebrae L4 and femur were removed and prepared for analysis. There were no differences in food intake, the body length or in bone measurements. Serum calcium decreased in the castrated groups. The level of phosphorus decreased and alkaline phosphatase increased in all groups. Some differences were observed among physical parameters. L4 vertebrae, immersed and wet weights increased with castration and the high fat diet, while the percentage of organic material and mineral decreased. In the jaws, immersed and wet weights and bone density increased with castration, but decreased with the combination spaying/fat diet. Bone volume and percentage of water decreased with intake of high fat diet. In the ashes of the jaws percentages of magnesium were increased in all groups, without changes in calcium and phosphorus. Groups fed with high-fat diets had lower resistance to the applied voltage in the jaw. It was demonstrated in these rats that, the deficiency of sex steroids associated with a high fat diet negatively influences mandibular bone integrity...


Assuntos
Animais , Camundongos , Antagonistas de Estrogênios/química , Dieta Hiperlipídica , Hiperlipidemias/induzido quimicamente , Fosfatase Alcalina , Densidade Óssea , Mandíbula , Fósforo
16.
Prensa méd. argent ; 99(2): 125-129, abr. 2013. ilus
Artigo em Espanhol | LILACS | ID: lil-699428

RESUMO

La leiomiomatosis intravenosa (LIV) es una patología poco frecuente caracterizada por la presencia de músculo liso en las venas miometriales del cuerpo uterino. Se presenta un caso de LIV limitado a cuello uterino y manguito vaginal. Se realizó histerectomía total con diagnóstico prequirúrgico de miomatosis uterina y menometrorragia. El diagnóstico de LIV fue anatomopatológico mediante técnicas de inmunohistoquímica. Si bien el 70 por ciento de las pacientes con LIV pueden ser curadas con cirugía, en un 30 por ciento de los casos existe persistencia o recurrencia a distancia de la enfermedad. En nuestro caso los controles a treinta meses de la cirugía fueron negativos e incluyeron estudios cardiovasculares, pulmonares, hepáticos y cerebrales.


Intravenous leiomyomatosis (IVL) cervicovaginal is an uncommon pathology, characterized by the presence of sooth muscle in the myometrial veins of the uterine body. A case of IVL is reported, limited to the cervix uteri and the vaginal muff. A total hysterctomy was performed, with presurgical diagnosis of uterine myomatosis and menometrorrhagia. The diagnosis of IVL was performed by clinicopathological analysis and by immunohistochemistry techniques. Although the 70 percent of the patients with IVL can be cured by surgery, in a 30 percentof the cases, there exists persistence and recurrency at distancy from the disease. In our case, the controls after 30 months since surgery were negatives, and included cardiovascular, pulmonary, hepatic and cerebral studies.


Assuntos
Feminino , Diagnóstico Precoce , Antagonistas de Estrogênios , Histerectomia , Incontinência Urinária de Urgência/terapia , Leiomiomatose/patologia , Metrorragia/patologia , Miométrio/patologia , Ovariectomia , Proliferação de Células
17.
Clinics ; 68(1): 101-106, Jan. 2013. ilus, tab
Artigo em Inglês | LILACS | ID: lil-665925

RESUMO

OBJECTIVE: The aim of this study was to evaluate the effect of oral tamoxifen treatment on the number of myofibroblasts present during the healing process after experimental bile duct injury. METHODS: The sample consisted of 16 pigs that were divided into two groups (the control and study groups). Incisions and suturing of the bile ducts were performed in the two groups. Tamoxifen (20 mg/day) was administered only to the study group. The animals were sacrificed after 30 days. Quantification of myofibroblasts in the biliary ducts was made through immunohistochemistry analysis using anti-alpha smooth muscle actin of the smooth muscle antibody. Immunohistochemical quantification was performed using a digital image system. RESULTS: In the animals treated with tamoxifen (20 mg/day), there was a significant reduction in immunostaining for alpha smooth muscle actin compared with the control group (0.1155 vs. 0.2021, p = 0.046). CONCLUSION: Tamoxifen reduced the expression of alpha smooth muscle actin in the healing tissue after bile duct injury, suggesting a decrease in myofibroblasts in the scarred area of the pig biliary tract. These data suggest that tamoxifen could be used in the prevention of biliary tract stenosis after bile duct surgeries.


Assuntos
Animais , Feminino , Ductos Biliares/lesões , Antagonistas de Estrogênios/uso terapêutico , Miofibroblastos/efeitos dos fármacos , Tamoxifeno/uso terapêutico , Cicatrização/efeitos dos fármacos , Actinas/análise , Actinas/efeitos dos fármacos , Ductos Biliares/efeitos dos fármacos , Contagem de Células , Imuno-Histoquímica , Músculo Liso/química , Músculo Liso/efeitos dos fármacos , Reprodutibilidade dos Testes , Suínos , Resultado do Tratamento
18.
Int. braz. j. urol ; 38(4): 512-518, July-Aug. 2012. ilus, tab
Artigo em Inglês | LILACS | ID: lil-649445

RESUMO

INTRODUCTION: Male testosterone deficiency is associated with bad sexual function and quality of life (QoL). The aim of this study was to determine whether a daily dose of 25 mg clomiphene citrate (CC) is effective in stimulating the endogenous testosterone production pathway and to address the applicability of this medication as a therapeutic option for symptomatic hypogonadism. MATERIALS AND METHODS: This was a prospective study. Men with low sexual desire and testosterone levels (T) below 400 ng/dL were selected to receive CC. Blood samples were obtained to determine baseline measurements of serum T, estradiol, LH, lipid profile and fasting plasma glucose. Each patient was treated with a daily dose of 25 mg CC for at least 3 months. Patients were asked if they experienced any side effects related to the use of CC and if they experienced any improvement in their sexual profile. Paired samples T-test was utilized to analyze responses to therapy. RESULTS: Our cohort consisted of 125 men with hypogonadism and low libido. Mean age was 62 years (± 11.1 years). Serum T levels ranged from 309 ng/dL (baseline, mean value) to 642 ng/dL (3 months after CC initiation, mean value) (p < 0.001). Serum cholesterol levels ranged from 197 to 186 mg/dL (p = 0.003). There were no statistically significant differences when comparing pre and post-treatment HDL-Cholesterol, triglycerides, fasting plasma glucose and prolactin. All men reported improvements in the post-treatment QoL scores. No serious adverse events were recorded. CONCLUSIONS: The CC was effective in stimulating the endogenous production of testosterone. A lower level of total cholesterol was verified after three months of treatment. This medication should be considered as a therapeutic option for some patients with symptomatic male testosterone deficiency.


Assuntos
Adulto , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Clomifeno/administração & dosagem , Antagonistas de Estrogênios/administração & dosagem , Hipogonadismo/tratamento farmacológico , Testosterona/deficiência , Fatores Etários , Métodos Epidemiológicos , Luminescência , Qualidade de Vida , Fatores de Tempo , Resultado do Tratamento , Testosterona/sangue , Testosterona/metabolismo
19.
Acta paul. enferm ; 25(2): 211-217, 2012. tab
Artigo em Português | LILACS, BDENF | ID: lil-622399

RESUMO

OBJETIVO: Examinar a relação entre as estratégias de enfrentamento adotadas por mulheres com câncer de mama em uso de tamoxifeno e as condições sociodemográficas. MÉTODOS: Estudo descritivo, transversal, com abordagem quantitativa. Os dados foram obtidos em entrevista realizada com 270 mulheres, com diagnóstico de câncer de mama em uso de tamoxifeno, usuárias do ambulatório Ylza Bianco, pertencente ao Hospital Santa Rita de Cássia, no Município de Vitória/ES. A análise foi realizada por meio SPSS - Versão 13,0 - 2004. RESULTADOS: Mulheres não letradas enfrentam o problema priorizando a busca de práticas religiosas (p<0,05); e mulheres com maior escolaridade, pertencentes à classe econômica B, com renda familiar superior a três salários mínimos e que vivem em área urbana empregam mais a estratégia de enfrentamento com foco no problema (p<0,05). CONCLUSÃO: A estratégia de enfrentamento adotada está associada a aspectos sociodemográficos.


OBJECTIVE: To examine the relationship among the coping strategies adopted by women with breast cancer using tamoxifen and sociodemographic conditions. METHODS: A cross-sectional study, with a quantitative approach. Data were obtained in an interview conducted with 270 women, with a diagnosis of breast cancer using tamoxifen, users of the outpatient Ylza Bianco center, belonging to the Hospital Santa Rita de Cássia, in Vitória / ES (Brazil). The analysis was performed using SPSS - Version 13.0 - 2004. RESULTS: Illiterate women faced the problem by prioritizing the search for religious practices (p <0.05); and women with higher education, belonging to economic class B, with family income more than three times the minimum wage and who lived in urban areas employ more coping strategies that are focused on the problem (p <0.05). CONCLUSION: The coping strategy adopted is associated with sociodemographic characteristics.


OBJETIVO: Examinar la relación entre las estrategias de enfrentamiento adoptadas por mujeres con cáncer de mama que usan tamoxifeno y las condiciones sociodemográficas. MÉTODOS: Estudio descriptivo, transversal, con abordaje cuantitativo. Los datos fueron obtenidos en entrevista realizada a 270 mujeres, con diagnóstico de cáncer de mama que usan tamoxifeno, usuarias del Consultorio Externo Ylza Bianco, perteneciente al Hospital Santa Rita de Cássia, en el Municipio de Vitória/ES. El análisis fue realizado por medio del SPSS - Versión 13,0 - 2004. RESULTADOS: Las mujeres no letradas enfrentan el problema priorizando la búsqueda de prácticas religiosas (p<0,05); y mujeres con mayor escolaridad, pertenecientes a la clase económica B, con ingreso familiar superior a tres salarios mínimos y que viven en área urbana emplean más la estrategia de enfrentamiento con foco en el problema (p<0,05). CONCLUSIÓN: La estrategia de enfrentamiento adoptada está asociada a aspectos sociodemográficos.


Assuntos
Humanos , Feminino , Adaptação Psicológica , Antagonistas de Estrogênios/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Religião , Condições Sociais , Tamoxifeno/uso terapêutico , Estudos Transversais , Epidemiologia Descritiva , Estudos de Avaliação como Assunto , Fatores Socioeconômicos
20.
Experimental & Molecular Medicine ; : 723-732, 2012.
Artigo em Inglês | WPRIM | ID: wpr-110120

RESUMO

Estrogen has anti-colorectal cancer effects which are thought to be mediated by mismatch repair gene (MMR) activity. Estrogen receptor (ER) expression is associated with microRNA (miRNA) expression in ER-positive tumors. However, studies of direct link between estrogen (especially estradiol E2), miRNA expression, and MMR in colorectal cancer (CRC) have not been done. In this study, we first evaluated the effects of estradiol (E2) and its antagonist ICI182,780 on the expression of miRNAs (miR-31, miR-155 and miR-135b) using COLO205, SW480 and MCF-7 cell lines, followed by examining the association of tissue miRNA expression and serum E2 levels using samples collected from 18 colorectal cancer patients. E2 inhibited the expressions of miRNAs in COLO205 cells, which could be reversed by E2 antagonist ICI 182.780. The expression of miR-135b was inversely correlated with serum E2 level and ER-beta mRNA expression in CRC patients' cancer tissues. There were significant correlations between serum E2 level and expression of ER-beta, miR-135b, and MMR in colon cancer tissue. This study suggests that the effects of estrogen on MMR function may be related to regulating miRNA expression via ER-beta, which may be the basis for the anti-cancer effect in colorectal cells.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Proteínas Adaptadoras de Transdução de Sinal/genética , Linhagem Celular Tumoral , Neoplasias Colorretais/genética , Reparo de Erro de Pareamento de DNA/genética , Estradiol/análogos & derivados , Antagonistas de Estrogênios/farmacologia , Receptor beta de Estrogênio/genética , Regulação Neoplásica da Expressão Gênica , MicroRNAs/genética , Proteína 2 Homóloga a MutS/genética , Proteínas Nucleares/genética , RNA Mensageiro/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA